Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist

• Published in: Endocrine Connections Vol. 14; no. 6
• Main Authors: Ovize, Michel, Allas, Soraya, Culler, Michael D, Milano, Stephane, Ouldrouis, Taha, Sumeray, Mark, van de Wetering de Rooij, Jeroen, Mannstadt, Michael
• Format: Journal Article
• Language: English
• Published: England Bioscientifica Ltd 01.06.2025; Bioscientifica
• Subjects: bone; calcium; hypoparathyroidism; kidney; parathormone; kidney; bone; hypoparathyroidism; calcium; parathormone
• ISSN: 2049-3614; 2049-3614
• DOI: 10.1530/EC-24-0464

This study evaluated the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of eneboparatide (AZP-3601), a novel agonist of the PTH receptor 1 developed for the treatment of hypoparathyroidism. This was a randomized, double-blind, placebo-controlled study. One-hundred four healthy volunteers were recruited into seven single ascending dose (SAD) and five multiple ascending dose (MAD) cohorts. PK parameters were time to peak, Cmax, area under the curve (AUC) and half-life. PD parameters included albumin-adjusted serum calcium (sCa), serum phosphorus (sPh), serum endogenous PTH, 24 hr urinary excretion of calcium (24 h-uCa), fractional excretion of calcium (FECa) and bone turnover markers (s-CTX and P1NP). There were no serious adverse events. All adverse events were of mild-to-moderate intensity. AUC and Cmax of eneboparatide increased with increasing doses. Time to maximum plasma concentration was 5-20 min. SAD showed a dose-dependent increase of sCa and decrease of sPh associated with a reduction of serum endogenous PTH. MAD demonstrated a rapid access to maximal PD effects and maintained levels of sCa throughout the day. Urinary excretion of calcium did not increase as a function of the dose of eneboparatide. P1NP and s-CTX did not change over the treatment period. The PD effects of eneboparatide were prolonged despite the short half-life. These data suggest that eneboparatide may provide sustained control of serum calcium in patients with hypoparathyroidism with once daily dosing. An open-label phase 2 study in patients with hypoparathyroidism has been recently completed and published and a phase 3 study has been initiated. NCT05239221.